SOUTH
SAN FRANCISCO, Calif., Sept. 5,
2023 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in upcoming investor relations events.
Citi 18th Annual BioPharma Conference
Wednesday, September 6th,
2023 at 1:00 PM ET
- Targeted Oncology Panel participation by Paul Stone, Chief Financial Officer, hosted
by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech
Analyst.
Morgan Stanley 21st Annual Global Healthcare
Conference
Monday, September 11th,
2023 at 10:40 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive
Officer, hosted by Ryuk Byun, MD, Executive Director.
A live audio webcast of conference events, as permitted by
conference host, will be available at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events and/or through the conference host.
A replay of available webcasts will be accessible for 30 days
following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Annual Report on Form 10-Q filed on August
10, 2023 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-september-2023-investor-relations-events-301916127.html
SOURCE IDEAYA Biosciences, Inc.